Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01402063 · ClinicalTrials.gov registry record · Phase 2
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
A Phase 2 study of Glioblastoma Multiforme, sponsored by Brown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 9
- Study locations
NCT01402063 is a Phase 2 study of Glioblastoma Multiforme that has completed, run by Brown University. The registered enrollment target is 63 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (34% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT01402063, a Phase 2 study of Glioblastoma Multiforme, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 9
- Study locations
Study Summary
To obtain preliminary data in a randomized phase II study whether PPX/RT improves progression-free survival as compared to temozolomide/RT for patients with GBM without MGMT methylation.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG PPX (CT2103)
Study Locations (9)
Pennsylvania
- PSU - Hershey
- Thomas Jefferson University Cancer Center - Philadelphia
California
- UCSD Cancer Center - La Jolla
Maine
- Maine Medical Center - Scarborough
Massachusetts
- UMASS Medical Center Cancer Center - Worcester
New York
- SUNY Medical Center - Syracuse
Rhode Island
- Rhode Island Hospital - Providence
Texas
- UT Southwestern Cancer Center - Dallas
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01402063
The ClinicalTrials.gov registry entry for NCT01402063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (34% lower). The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT01402063 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Pennsylvania, California, Maine.
Frequently Asked Questions
What is clinical trial NCT01402063 about?
NCT01402063 is a clinical study titled "PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation". To obtain preliminary data in a randomized phase II study whether PPX/RT improves progression-free survival as compared to temozolomide/RT for patients with GBM without MGMT methylation.
What is the current status of trial NCT01402063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2011-09. Estimated completion is 2015-06.
What conditions does trial NCT01402063 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT01402063?
The interventions under investigation include: Temozolomide (DRUG), PPX (CT2103) (DRUG).
Who is sponsoring clinical trial NCT01402063?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01402063 being conducted?
This trial has 9 study locations across California, Maine, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.